Pub. Date : 2017 Apr
PMID : 28375409
2 Functional Relationships(s)Download |
Sentence | Compound Name | Protein Name | Organism |
1 | The Vioxx Gastrointestinal Outcomes Research (VIGOR) trial, published in 2000, was the first to raise concerns that NSAIDs (specifically, the COX-2 selective inhibitor rofecoxib) might be associated with a higher risk for cardiovascular (CV) events. | rofecoxib | mitochondrially encoded cytochrome c oxidase II | Homo sapiens |
2 | The Vioxx Gastrointestinal Outcomes Research (VIGOR) trial, published in 2000, was the first to raise concerns that NSAIDs (specifically, the COX-2 selective inhibitor rofecoxib) might be associated with a higher risk for cardiovascular (CV) events. | rofecoxib | mitochondrially encoded cytochrome c oxidase II | Homo sapiens |